Physician profile
Mary Watson Keith
NPI 1194073460
$1,583.66
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209 · 2020: $462 · 2021: $826 · 2023: $51.34 · 2024: $36.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $87.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $87.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $251.93 | 2019-2021 | |
| Abbvie INC. | $244.59 | 2021 | |
| Allergan, INC. | $170.61 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.40 | 2019-2023 | Ofev |
| Biohaven Pharmaceuticals, INC. | $110.41 | 2021 | |
| Paratek Pharmaceuticals, INC. | $106.28 | 2020-2021 | |
| Astrazeneca Pharmaceuticals Lp | $67.79 | 2019-2020 | |
| Esperion Therapeutics, INC. | $65.99 | 2020-2021 | |
| Dexcom, INC. | $59.70 | 2021 | |
| Pfizer INC. | $59.60 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $45.86 | 2020-2021 | |
| Lilly USA, LLC | $37.30 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $29.03 | 2019-2020 | |
| Genentech USA, INC. | $26.58 | 2020-2021 | |
| Glaxosmithkline, LLC. | $25.31 | 2019-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $21.72 | 2024 | Glassia |
| Abbott Laboratories | $21.15 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.00 | 2019 | |
| Novo Nordisk INC | $19.01 | 2021 | |
| Cranial Technologies, INC | $16.61 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $15.87 | 2021 | |
| Baxter Healthcare | $14.76 | 2023 | |
| Mylan Specialty L.P. | $14.69 | 2019 | |
| Collegium Pharmaceutical, INC. | $14.47 | 2024 | Belbuca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Keith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.